Published in Psychiatry Res on March 11, 2010
Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. Biol Psychiatry (2012) 1.47
Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry (2012) 1.27
Biomarkers and clinical staging in psychiatry. World Psychiatry (2014) 1.22
Developmental meta-analyses of the functional neural correlates of bipolar disorder. JAMA Psychiatry (2014) 0.89
Differentiating patterns of amygdala-frontal functional connectivity in schizophrenia and bipolar disorder. Schizophr Bull (2013) 0.88
Expression profiling in neuropsychiatric disorders: emphasis on glutamate receptors in bipolar disorder. Pharmacol Biochem Behav (2011) 0.85
Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia. Eur Arch Psychiatry Clin Neurosci (2014) 0.84
Postnatal development of the amygdala: A stereological study in macaque monkeys. J Comp Neurol (2012) 0.84
Disturbed cortico-amygdalar functional connectivity as pathophysiological correlate of working memory deficits in bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Mood-state effects on amygdala volume in bipolar disorder. J Affect Disord (2012) 0.80
Intrinsic Amygdala Functional Connectivity in Youth With Bipolar I Disorder. J Am Acad Child Adolesc Psychiatry (2015) 0.78
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry (2006) 3.35
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Acamprosate for alcohol dependence. Cochrane Database Syst Rev (2010) 3.03
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry (2005) 2.84
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry (2011) 2.75
Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry (2005) 2.55
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2009) 2.33
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (2010) 2.21
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 2.13
Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage (2011) 2.02
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2009) 1.86
Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry (2007) 1.85
Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry (2007) 1.71
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 1.62
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol (2004) 1.56
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev (2010) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia (2012) 1.44
Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2011) 1.41
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2014) 1.38
[The confused patient]. MMW Fortschr Med (2014) 1.38
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Effects of antipsychotics on brain structure. Curr Opin Psychiatry (2006) 1.33
Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology (2010) 1.28
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev (2008) 1.25
Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. Am J Psychiatry (2004) 1.24
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24
Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna) (2009) 1.22
Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol (2011) 1.21
Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry (2006) 1.21
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull (2013) 1.18
Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 1.18
Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci (2011) 1.18
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci (2010) 1.17
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry (2010) 1.17
Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res (2009) 1.16
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord (2005) 1.12
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2005) 1.11
The effects of physical exercise in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.11
Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry (2010) 1.11
Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. Bipolar Disord (2012) 1.11
Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev (2010) 1.10
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry (2010) 1.10
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol (2008) 1.10
Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. Psychiatry Res (2007) 1.09
Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res (2007) 1.09
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 1.06
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem (2004) 1.05
Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci (2007) 1.05
"How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. Psychiatr Serv (2011) 1.05
Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev (2010) 1.04
Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res (2011) 1.04
Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci (2011) 1.04
Valproate for schizophrenia. Cochrane Database Syst Rev (2008) 1.03
Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg (2007) 1.03
Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res (2003) 1.03
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol (2011) 1.03
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety (2009) 1.01
How to obtain NNT from Cohen's d: comparison of two methods. PLoS One (2011) 1.01
A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia. EMBO Mol Med (2011) 1.00
Hippocampal deformities in the unaffected siblings of schizophrenia subjects. Biol Psychiatry (2003) 1.00
Impulsive personality and the ability to resist immediate reward: an fMRI study examining interindividual differences in the neural mechanisms underlying self-control. Hum Brain Mapp (2011) 0.99
Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry (2010) 0.98
Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 0.98
Articulatory rehearsal in verbal working memory: a possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neurosci Lett (2006) 0.98
Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res (2006) 0.98
The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophr Res (2002) 0.97
Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry (2010) 0.97
The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol (2007) 0.96
CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2013) 0.94
Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. Brain Stimul (2011) 0.94
Reduced prefrontal gyrification in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.94